DK3535260T3 - Nitrogen-containing heterocyclic compounds as fxr modulators - Google Patents
Nitrogen-containing heterocyclic compounds as fxr modulators Download PDFInfo
- Publication number
- DK3535260T3 DK3535260T3 DK17801164.9T DK17801164T DK3535260T3 DK 3535260 T3 DK3535260 T3 DK 3535260T3 DK 17801164 T DK17801164 T DK 17801164T DK 3535260 T3 DK3535260 T3 DK 3535260T3
- Authority
- DK
- Denmark
- Prior art keywords
- nitrogen
- containing heterocyclic
- heterocyclic compounds
- fxr modulators
- fxr
- Prior art date
Links
- -1 Nitrogen-containing heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610974016.1A CN108017636A (zh) | 2016-11-04 | 2016-11-04 | 作为fxr调节剂的含氮杂环化合物 |
| US201662424813P | 2016-11-21 | 2016-11-21 | |
| PCT/US2017/058802 WO2018085148A1 (en) | 2016-11-04 | 2017-10-27 | Nitrogen-containing heterocyclic compounds as fxr modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3535260T3 true DK3535260T3 (en) | 2023-10-23 |
Family
ID=62076166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17801164.9T DK3535260T3 (en) | 2016-11-04 | 2017-10-27 | Nitrogen-containing heterocyclic compounds as fxr modulators |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10919903B2 (da) |
| EP (1) | EP3535260B1 (da) |
| JP (1) | JP7208909B2 (da) |
| KR (1) | KR102553578B1 (da) |
| CN (2) | CN108017636A (da) |
| AU (1) | AU2017354873C1 (da) |
| CA (1) | CA3042400A1 (da) |
| DK (1) | DK3535260T3 (da) |
| ES (1) | ES2964945T3 (da) |
| WO (1) | WO2018085148A1 (da) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10457703B2 (en) | 2015-03-31 | 2019-10-29 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| EP3523298A4 (en) | 2016-10-04 | 2020-06-24 | Enanta Pharmaceuticals, Inc. | ISOXAZOLANALOGA AS FXR AGONISTS AND METHOD FOR USE THEREOF |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| MX2021012750A (es) * | 2019-04-19 | 2021-11-18 | Shanghai Inst Materia Medica Cas | Agonista de molécula pequeña del fxr y método de preparación para el mismo y uso del mismo. |
| CN111825667B (zh) * | 2019-04-19 | 2023-07-25 | 中国科学院上海药物研究所 | Fxr小分子激动剂及其制备方法和用途 |
| US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| TW202114671A (zh) | 2019-07-23 | 2021-04-16 | 瑞士商諾華公司 | 包含fxr促效劑之治療 |
| CN114126657A (zh) | 2019-07-23 | 2022-03-01 | 诺华股份有限公司 | 使用fxr激动剂的肝脏疾病的组合治疗 |
| AU2020341135A1 (en) | 2019-09-03 | 2022-04-07 | Novartis Ag | Treatment of liver disease or disorder comprising ActRII receptor antagonists |
| CN114401745A (zh) | 2019-09-19 | 2022-04-26 | 诺华股份有限公司 | 包含fxr激动剂的治疗 |
| EP4041233A1 (en) | 2019-09-30 | 2022-08-17 | Novartis AG | Treatment comprising the use of fxr agonists |
| US20230060422A1 (en) | 2019-12-20 | 2023-03-02 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| MX2022011902A (es) | 2020-03-26 | 2023-01-04 | Janssen Pharmaceutica Nv | Moduladores de la monoacilglicerol lipasa. |
| CN112083113B (zh) * | 2020-07-09 | 2021-06-15 | 苏州旭辉检测有限公司 | 一种螺环化合物的生物样品分析方法 |
| IL300155A (en) | 2020-08-06 | 2023-03-01 | Gasherbrum Bio Inc | Heterocyclic GLP-1 agonists |
| CN116406360A (zh) | 2020-08-28 | 2023-07-07 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| CN116547278A (zh) * | 2020-10-13 | 2023-08-04 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
| CN118742306A (zh) * | 2022-01-17 | 2024-10-01 | 和博医药有限公司 | 苯并噻唑-哌嗪基-噁唑化合物的固体形式及其使用方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| AU2007212126B2 (en) | 2006-02-03 | 2012-07-19 | Eli Lilly And Company | Compounds and methods for modulating FX-receptors |
| WO2009005998A1 (en) | 2007-07-02 | 2009-01-08 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2655369A1 (en) | 2010-12-20 | 2013-10-30 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| WO2012087520A1 (en) * | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| ES2846183T3 (es) | 2013-09-11 | 2021-07-28 | Inst Nat Sante Rech Med | Métodos y composiciones farmacéuticas para el tratamiento de la infección por el virus de la hepatitis B |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| TN2017000243A1 (en) * | 2014-12-18 | 2018-10-19 | Novartis Ag | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
| CN106946867B (zh) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| PL3419624T3 (pl) * | 2016-02-22 | 2021-08-02 | Novartis Ag | Sposoby stosowania agonistów fxr |
| US10080742B2 (en) * | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2018039384A1 (en) * | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators |
| EP3523298A4 (en) * | 2016-10-04 | 2020-06-24 | Enanta Pharmaceuticals, Inc. | ISOXAZOLANALOGA AS FXR AGONISTS AND METHOD FOR USE THEREOF |
-
2016
- 2016-11-04 CN CN201610974016.1A patent/CN108017636A/zh active Pending
-
2017
- 2017-10-27 KR KR1020197015543A patent/KR102553578B1/ko active IP Right Grant
- 2017-10-27 AU AU2017354873A patent/AU2017354873C1/en active Active
- 2017-10-27 US US16/346,807 patent/US10919903B2/en active Active
- 2017-10-27 CN CN201780067659.0A patent/CN109963849B/zh active Active
- 2017-10-27 WO PCT/US2017/058802 patent/WO2018085148A1/en unknown
- 2017-10-27 EP EP17801164.9A patent/EP3535260B1/en active Active
- 2017-10-27 ES ES17801164T patent/ES2964945T3/es active Active
- 2017-10-27 CA CA3042400A patent/CA3042400A1/en active Pending
- 2017-10-27 DK DK17801164.9T patent/DK3535260T3/da active
- 2017-10-27 JP JP2019544791A patent/JP7208909B2/ja active Active
-
2020
- 2020-12-01 US US17/108,644 patent/US20210079006A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP7208909B2 (ja) | 2023-01-19 |
| KR20190071801A (ko) | 2019-06-24 |
| AU2017354873A1 (en) | 2019-05-23 |
| ES2964945T3 (es) | 2024-06-11 |
| EP3535260B1 (en) | 2023-08-30 |
| JP2020500211A (ja) | 2020-01-09 |
| AU2017354873C1 (en) | 2023-05-18 |
| US20210079006A1 (en) | 2021-03-18 |
| US10919903B2 (en) | 2021-02-16 |
| EP3535260A1 (en) | 2019-09-11 |
| WO2018085148A1 (en) | 2018-05-11 |
| CN109963849B (zh) | 2023-03-28 |
| KR102553578B1 (ko) | 2023-07-10 |
| AU2017354873B2 (en) | 2021-10-21 |
| CA3042400A1 (en) | 2018-05-11 |
| US20190276465A1 (en) | 2019-09-12 |
| CN108017636A (zh) | 2018-05-11 |
| CN109963849A (zh) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3535260T3 (en) | Nitrogen-containing heterocyclic compounds as fxr modulators | |
| IL263825A (en) | Heterocyclic compounds as immunomodulators | |
| ZA201807249B (en) | Heterocyclic compound | |
| IL263495A (en) | Modulating compounds (fxr (nr1h4 | |
| IL263493B (en) | Modulating compounds (fxr (nr1h4 | |
| HK1223100A1 (zh) | 雜環化合物 | |
| LT3371190T (lt) | Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai | |
| EP3156397A4 (en) | Nitrogen-containing heterocyclic compound | |
| EP3144308A4 (en) | Nitrogen-containing heterocyclic compound | |
| HK1249105A1 (zh) | 含氮雜環化合物 | |
| EP3693360C0 (en) | HETEROCYCLIC COMPOUNDS | |
| PT3268356T (pt) | Compostos heterocíclicos e métodos para a sua utilização | |
| IL266099A (en) | Heterocyclic composition | |
| GB201401792D0 (en) | Beta-lactam compounds |